ArticleFrontiers in pharmacology2021

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.

Beatriz Orts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.